Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ioannis Pyrousis"'
Autor:
Arezina Kasti, Maroulla Nikolaki, Kalliopi Synodinou, Konstantinos Katsas, Konstantinos Petsis, Sophia Lambrinou, Ioannis Pyrousis, Konstantinos Triantafyllou
Publikováno v:
Microorganisms. 10(4)
Stevia, a zero-calorie sugar substitute, is recognized as safe by the Food and Drug Administration (FDA) and the European Food Safety Authority (EFSA). In vitro and in vivo studies showed that stevia has antiglycemic action and antioxidant effects in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e483d14ef81e8c9847c7febdce8e101
https://pubmed.ncbi.nlm.nih.gov/35456796
https://pubmed.ncbi.nlm.nih.gov/35456796
Autor:
Kalliopi D. Synodinou, Ioannis Pyrousis, Konstantinos Triantafyllou, Arezina N. Kasti, Maroulla D. Nikolaki
Publikováno v:
Microorganisms, Vol 9, Iss 2376, p 2376 (2021)
Microorganisms
Microorganisms
Inflammasomes are cytoplasmic multiprotein complexes formed by the host’s immune system as a response to microbial infection and cellular damage. Many studies have revealed various regulators of NOD-, LRR-, and pyrin domain-containing protein 3 (NL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a53c72930172ad64439a13bfc1f780e8
https://www.mdpi.com/2076-2607/9/11/2376
https://www.mdpi.com/2076-2607/9/11/2376
Autor:
Ioannis Pyrousis, Konstantinos Triantafyllou, Arezina N. Kasti, Kalliopi D. Synodinou, Maroulla D. Nikolaki, Nikolaos Oikonomopoulos
Publikováno v:
Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral NutritionREFERENCES. 37(2)
Mitochondrial neurogastrointestinal encephalopathy (MNGIE) is a rare, inherited, multisystemic autosomal recessive disorder caused by mutations in the nuclear TYMP gene. This syndrome is characterized by ptosis, external ophthalmoplegia, gastrointest
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0a50cd0a3569cb5a9c67bdd9ebd9795
https://pubmed.ncbi.nlm.nih.gov/34170051
https://pubmed.ncbi.nlm.nih.gov/34170051
Autor:
Foteinos-Ioannis D. Dimtrakopoulos, Petros Christopoulos, Mariam Elshiaty, Lea Daniello, Ioannis Pyrousis, Anastasia E Kottorou, Thomas Makatsoris, Haralabos Kalofonos, Angelos Koutras
Publikováno v:
Journal of Clinical Oncology. 40:e21096-e21096
e21096 Background: Ιmmune checkpoint inhibitors (ICIs) have tremendously changed the daily clinical practice on the treatment of advanced non-small cell lung cancer (aNSCLC). However, clinical useful biomarkers remain an unmet need. Recently, a new
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::66482380fb7f5a2dffbab1d0ea8b2b05
https://doi.org/10.1200/jco.2022.40.16_suppl.e21096
https://doi.org/10.1200/jco.2022.40.16_suppl.e21096
Autor:
Fotini Kalofonou, Angelos Koutras, Foteinos-Ioannis Dimitrakopoulos, Ioannis Pyrousis, Achilleas Nikolakopoulos, Haralabos P. Kalofonos, Theodora Frantzi, Thomas Makatsoris, Elias Liolis, Anastasia E. Kottorou
Publikováno v:
Cancers
Volume 12
Issue 5
Cancers, Vol 12, Iss 1257, p 1257 (2020)
Volume 12
Issue 5
Cancers, Vol 12, Iss 1257, p 1257 (2020)
Immunotherapy with immune checkpoint inhibitors (ICIs) has changed the therapeutic management of advanced non-small cell lung cancer (aNSCLC) over the last decade. However, there is an unmet need for clinically useful biomarkers in this patient subgr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41066b9f601a4deeca4cfee40bb4e76e
http://europepmc.org/articles/PMC7280986
http://europepmc.org/articles/PMC7280986
Autor:
Anastasia E. Kottorou, Achilleas Nikolakopoulos, Haralabos P. Kalofonos, Angelos Koutras, Thomas Makatsoris, Elias Liolis, Foteinos-Ioannis Dimitrakopoulos, Ioannis Pyrousis, Theodora Frantzi, Foteini Kalofonou
Publikováno v:
Journal of Clinical Oncology. 38:e21507-e21507
e21507 Background: With the exception of programmed death ligand 1 (PD-L1) expression and Tumour Mutational Burden (TMB), which have entered clinical practice, no other clinically useful predictive biomarker for immune checkpoint inhibitors (ICIs) ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1cdbeef5e01dd7eead631b479e123105
https://doi.org/10.1200/jco.2020.38.15_suppl.e21507
https://doi.org/10.1200/jco.2020.38.15_suppl.e21507